Nothing Special   »   [go: up one dir, main page]

AU1028097A - Tri-aryl ethane derivatives as pde iv inhibitors - Google Patents

Tri-aryl ethane derivatives as pde iv inhibitors

Info

Publication number
AU1028097A
AU1028097A AU10280/97A AU1028097A AU1028097A AU 1028097 A AU1028097 A AU 1028097A AU 10280/97 A AU10280/97 A AU 10280/97A AU 1028097 A AU1028097 A AU 1028097A AU 1028097 A AU1028097 A AU 1028097A
Authority
AU
Australia
Prior art keywords
pde
tri
inhibitors
ethane derivatives
aryl ethane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU10280/97A
Other versions
AU707574B2 (en
Inventor
Marc Blouin
Yves Ducharme
Mario Girard
Yves Girard
Daniel Guay
Pierre Hamel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Frosst Canada and Co
Original Assignee
Merck Frosst Canada and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606377.1A external-priority patent/GB9606377D0/en
Application filed by Merck Frosst Canada and Co filed Critical Merck Frosst Canada and Co
Publication of AU1028097A publication Critical patent/AU1028097A/en
Assigned to MERCK FROSST CANADA & CO. reassignment MERCK FROSST CANADA & CO. Alteration of Name(s) of Applicant(s) under S113 Assignors: MERCK FROSST CANADA INC.
Application granted granted Critical
Publication of AU707574B2 publication Critical patent/AU707574B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
AU10280/97A 1995-12-15 1996-12-11 Tri-aryl ethane derivatives as PDE IV inhibitors Ceased AU707574B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US870495P 1995-12-15 1995-12-15
US60/008704 1995-12-15
GB9606377 1996-03-26
GBGB9606377.1A GB9606377D0 (en) 1996-03-26 1996-03-26 Tri-aryl ethane derivatives as PDE IV inhibitors
PCT/CA1996/000839 WO1997022586A1 (en) 1995-12-15 1996-12-11 Tri-aryl ethane derivatives as pde iv inhibitors

Publications (2)

Publication Number Publication Date
AU1028097A true AU1028097A (en) 1997-07-14
AU707574B2 AU707574B2 (en) 1999-07-15

Family

ID=26308993

Family Applications (1)

Application Number Title Priority Date Filing Date
AU10280/97A Ceased AU707574B2 (en) 1995-12-15 1996-12-11 Tri-aryl ethane derivatives as PDE IV inhibitors

Country Status (5)

Country Link
EP (1) EP0873311A1 (en)
JP (1) JP3465825B2 (en)
AU (1) AU707574B2 (en)
CA (1) CA2238875C (en)
WO (1) WO1997022586A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69826286T2 (en) 1997-06-27 2005-11-24 Fujisawa Pharmaceutical Co., Ltd. DERIVATIVES WITH AN AROMATIC RING
PL347109A1 (en) 1998-10-06 2002-03-25 Dainippon Pharmaceutical Co 2,3-disubstituted pyridine derivatives, process for the preparation thereof, drug compositions containing the same and intermediates for the preparation
US6180650B1 (en) * 1999-04-23 2001-01-30 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
US6200993B1 (en) * 1999-05-05 2001-03-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE4 inhibitors
CN1202865C (en) 1999-08-21 2005-05-25 奥坦纳医药公司 Synergistic combination
AU2002229611A1 (en) * 2000-12-08 2002-06-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of active compounds capable of modulating the intracellular pathway triggered by the dp receptor in langerhans cells
KR20040007596A (en) 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 Compositions for promoting healing of bone fracture
ES2427930T3 (en) 2001-05-23 2013-11-04 Mitsubishi Tanabe Pharma Corporation Therapeutic composition for the regenerative treatment of cartilage diseases
CN100513397C (en) * 2002-11-19 2009-07-15 记忆药物公司 Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors
EP3798214B1 (en) 2014-10-06 2022-09-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CA3019380A1 (en) 2016-03-31 2017-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
HUE056716T2 (en) 2016-09-30 2022-03-28 Vertex Pharma Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
DK3551622T3 (en) 2016-12-09 2020-11-23 Vertex Pharma MODULATOR OF TRANSMEMBRANE CONDUCTANCE REGULATOR OF CYSTIC FIBROSE, PHARMACEUTICAL COMPOSITIONS, TREATMENT PROCEDURES AND METHOD OF MANUFACTURE OF THE MODULATOR
CA3066084A1 (en) 2017-06-08 2018-12-13 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CA3069226A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AU2018309043B2 (en) 2017-08-02 2022-03-31 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
TWI719349B (en) 2017-10-19 2021-02-21 美商維泰克斯製藥公司 Crystalline forms and compositions of cftr modulators
AU2018380426B2 (en) 2017-12-08 2023-05-18 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (en) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 Pharmaceutical compositions for treating cystic fibrosis
WO2019200246A1 (en) 2018-04-13 2019-10-17 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW263495B (en) * 1992-12-23 1995-11-21 Celltech Ltd
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9326173D0 (en) * 1993-12-22 1994-02-23 Celltech Ltd Chemical compounds and process
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation

Also Published As

Publication number Publication date
CA2238875A1 (en) 1997-06-26
AU707574B2 (en) 1999-07-15
CA2238875C (en) 2003-09-16
WO1997022586A1 (en) 1997-06-26
JP3465825B2 (en) 2003-11-10
EP0873311A1 (en) 1998-10-28
JP2000501742A (en) 2000-02-15

Similar Documents

Publication Publication Date Title
AU1027997A (en) Diphenyl pyridyl ethane derivatives as pde iv inhibitors
AU1028097A (en) Tri-aryl ethane derivatives as pde iv inhibitors
AU7254196A (en) Benzimidazole derivatives as 15-lo inhibitors
AU2747395A (en) Substituted oxime derivatives useful as pde iv inhibitors
AU1301697A (en) Tyrosin-derivate as alpha-v-integrin inhibitors
AU7631496A (en) Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
GB2308366B (en) Tri-substituted phenyl derivatives useful as PDE IV inhibitors
AU4436396A (en) Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
AU6622396A (en) 4-mercaptopyrrolidine derivatives as farnesyl transferase inhibitors
AU7692696A (en) Heteroaryl derivatives
AU5324996A (en) Protein kinase c inhibitors
AU6718494A (en) 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
AU6419296A (en) Cyclic gmp-specific phosphodiesterase inhibitors
AU4791797A (en) 6-phenylpyridyl-2-amine derivatives useful as nos inhibitors
AU4665596A (en) Pyrazolylbenzoyl derivatives
AU7370096A (en) Bis-heteroarylylmethoxyphenylketone derivatives as inhibitors of leukotriene biosynthesis
AU1195897A (en) Heteroarylcarboxamide derivatives
AU4086296A (en) Indolepiperidine derivatives
AU4875296A (en) Isoxazolyl-benzoyl derivatives
AU6734296A (en) Bicyclic lactam derivatives as thrombin inhibitors
AU4779297A (en) Pde iv inhibiting 2-cyanoiminoimidazole derivatives
AU5763596A (en) 2-ureido-benzamide derivatives
AU7570996A (en) Quinoline derivatives as type iv phosphodiesterase inhibitors
AU1605699A (en) Substituted 3-amino-2-hydroxyphenylacetamide derivatives as enzyme inhibitors (ii)
AU6191796A (en) Sulfonyl- or sulfinylbenzoylguanidine derivatives

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired